• +353-1-415-1241(GMT OFFICE HOURS)
  • 1-800-526-8630(US/CAN TOLL FREE)
  • 1-917-300-0470(EST OFFICE HOURS)
Pricing and Reimbursement in Generics - European Austerity Measures and Healthcare Cost Containment Puts Innovation-Driven Pharma Companies under Pressure - Product Image

Pricing and Reimbursement in Generics - European Austerity Measures and Healthcare Cost Containment Puts Innovation-Driven Pharma Companies under Pressure

  • Published: April 2012
  • Region: Europe
  • 99 Pages
  • GBI Research

GBI Research, the leading business intelligence provider, has released its latest research “Pricing and Reimbursement in Generics - European Austerity Measures and Healthcare Cost Containment Puts Innovation-Driven Pharma Companies under Pressure”. The report provides a comprehensive overview of the healthcare expenditure, healthcare regulatory system, and pricing and reimbursement process with key data, information and analysis of pricing and reimbursement decisions, across 19 countries. The report closely scrutinizes the major changes in generic drugs-related pricing and reimbursement in the 19 countries over recent years and whose impact will be felt in the near future. It also describes the efforts taken by the governing bodies in shaping the pricing and reimbursement policies of generic drugs.

GBI Research has found that expenditure towards healthcare has shown an increasing trend in most of the countries due to rising costs, resulting in budget deficits. In order to save costs, many countries have adopted reference pricing as it helps lower drug costs. Plans to increase generic drug prescription and low-cost generic drug use are being implemented in order to READ MORE >

1.1 List of Tables
1.2 List of Figures

2 Pricing and Reimbursement in Generics - Introduction
2.1 GBI Research Report Guidance

3 Pricing and Reimbursement in Generics - The US
3.1 Health Insurance
3.1.1 Health Insurance Coverage
3.1.2 Health Insurance Providers
3.2 Major Agencies Involved
3.3 Structure of Regulatory System
3.4 Pricing of Generics in the US
3.4.1 340B Drug Pricing Program
3.5 Reimbursement of Generics in the US
3.5.1 Health Insurance Companies
3.5.2 Pharmacy Benefit Managers
3.5.3 Reimbursement Programs in the US
3.6 Case Study
3.6.1 Pricing and Reimbursement in Oncology
3.7 Key Trends
3.7.1 Increased Availability of Generic Drugs
3.7.2 Patient Protection and Affordable Care Act to Tackle Soaring Prescription Drug Prices
3.7.3 Significant Decrease in Average Price of Generic Drugs
3.7.4 Generic Drugs Rebates to be Aligned for Medicare and Medicaid
3.7.5 Lower FEHB Drug Costs
3.7.6 Medicare Part D Changes in Standard Benefit Parameters
3.7.7 Cost-sharing of Generic Drugs
3.7.8 Penalty for Anemia Drug Overuse
3.7.9 Generic Price War at Retail Sector
3.8 Major Challenges
3.8.1 Medicare Part B Drug Pricing Does Not Accurately Reflect Market Price
3.8.2 Renewal of Medicaid Drug Payment Policy
3.8.3 Proposed Cuts in Medicare Part B Reimbursement
3.8.4 New Trend in Free Trade Agreements Could Affect Healthcare Programs

4 Pricing and Reimbursement in Generics - The Top Five Countries of Europe
4.1 The UK
4.1.1 Pricing and Reimbursement Process
4.1.2 Key Trends
4.1.3 Major Challenges
4.2 France
4.2.1 Pricing and Reimbursement Process
4.2.2 Key Trends
4.2.3 Major Challenges
4.3 Germany
4.3.1 Pricing and Reimbursement Process
4.3.2 Key Trends
4.3.3 Major Challenges
4.4 Italy
4.4.1 Pricing and Reimbursement Process
4.4.2 Key Trends
4.4.3 Major Challenges
4.5 Spain
4.5.1 Pricing and Reimbursement Process
4.5.2 Key Trends
4.5.3 Major Challenges

5 Pricing and Reimbursement in Generics - Eastern Europe
5.1 Czech Republic
5.1.1 Pricing and Reimbursement Process
5.1.2 Key Trends
5.1.3 Major Challenges
5.2 Poland
5.2.1 Pricing and Reimbursement Process
5.2.2 Key Trends
5.2.3 Major Challenges
5.3 Austria
5.3.1 Pricing and Reimbursement Process
5.3.2 Key Trends
5.4 Romania
5.4.1 Pricing and Reimbursement Process
5.4.2 Key Trends
5.4.3 Major Challenges
5.4.4 Case Study
5.5 Hungary
5.5.1 Pricing and Reimbursement Process
5.5.2 Key Trends
5.5.3 Major Challenges

6 Pricing and Reimbursement in Generics - Scandinavia
6.1 Norway
6.1.1 Pricing and Reimbursement Process
6.1.2 Key Trends
6.2 Sweden
6.2.1 Pricing and Reimbursement Process
6.2.2 Major Challenges
6.3 Finland
6.3.1 Pricing and Reimbursement Process
6.4 Denmark
6.4.1 Pricing and Reimbursement Process
6.4.2 Key Trends

7 Pricing and Reimbursement in Generics - Asia-Pacific
7.1 Japan
7.1.1 Pricing and Reimbursement Process
7.1.2 Key Trends
7.1.3 Major Challenges
7.2 Australia
7.2.1 Pricing and Reimbursement Process
7.2.2 Key Trends
7.2.3 Major Challenges
7.3 China
7.3.1 Pricing and Reimbursement Process
7.3.2 Key Trends
7.3.3 Major Challenges
7.4 India
7.4.1 Pricing and Reimbursement Process
7.4.2 Key Trends
7.4.3 Major Challenges

8 Pricing and Reimbursement in Generics - Appendix
8.1 Market Definitions
8.2 Abbreviations
8.3 Research Methodology
8.3.1 The US
8.3.2 Top Five Countries of Europe
8.3.3 Eastern Europe
8.3.4 Scandinavia
8.3.5 Asia-Pacific
8.4 Contact Us
8.5 Disclaimer
8.6 Sources

1.1 List of Tables

Table 1: Pricing and Reimbursement in Generics, The US, Average Retail Coinsurance Rates, By Tier (%), 2009
Table 2: Pricing and Reimbursement in Generics, The US, Reimbursement Programs, 2011
Table 3: Pricing and Reimbursement in Generics, The US, State Discount Programs, 2011
Table 4: Pricing and Reimbursement in Generics, The US, Annual Price Index Change in Prescription Drugs (%), 2008-2010
Table 5: Pricing and Reimbursement in Generics, The US, Annual Retail Price Index Change in Generic Drugs (%), 2008-2010
Table 6: Pricing and Reimbursement in Generics, The US, Medicare Part D Changes in Standard Benefit Parameters ($), 2008-2012
Table 7: Pricing and Reimbursement in Generics, The US, Generic Drug Cost-Sharing (%), 2011-2020
Table 8: Pricing and Reimbursement in Generics, The UK, Healthcare Expenditure, 2009
Table 9: Pricing and Reimbursement in Generics, France, Healthcare Expenditure, 2009
Table 10: Pricing and Reimbursement in Generics, Germany, Healthcare Expenditure, 2009
Table 11: Pricing and Reimbursement in Generics, Italy, Healthcare Expenditure, 2009-2010
Table 12: Pricing and Reimbursement in Generics, Spain, Healthcare Expenditure, 2009
Table 13: Pricing and Reimbursement in Generics, Czech Republic, Healthcare Expenditure, 2009
Table 14: Pricing and Reimbursement in Generics, Poland, Healthcare Expenditure, 2009
Table 15: Pricing and Reimbursement in Generics, Austria, Healthcare Expenditure, 2009
Table 16: Pricing and Reimbursement in Generics, Austria, Box Model for Reimbursement, 2011
Table 17: Pricing and Reimbursement in Generics, Hungary, Healthcare Expenditure, 2009
Table 18: Pricing and Reimbursement in Generics, Norway, Healthcare Expenditure, 2009
Table 19: Pricing and Reimbursement in Generics, Norway, Reimbursement Categories of Medicines, 2011
Table 20: Pricing and Reimbursement in Generics, Sweden, Healthcare Expenditure, 2009
Table 21: Pricing and Reimbursement in Generics, Sweden, Retail Sales Price, 2011
Table 22: Pricing and Reimbursement in Generics, Sweden, Patient Co-payments, 2011
Table 23: Pricing and Reimbursement in Generics, Finland, Healthcare Expenditure, 2009-2010
Table 24: Pricing and Reimbursement in Generics, Denmark, Healthcare Expenditure, 2009
Table 25: Pricing and Reimbursement in Generics, Denmark, Reimbursement Thresholds, 2011
Table 26: Pricing and Reimbursement in Generics, Japan, Healthcare Expenditure, 2009
Table 27: Pricing and Reimbursement in Generics, Japan, Trend in Revision Rates of Reimbursement Prices, 1992-2008
Table 28: Pricing and Reimbursement in Generics, Australia, Healthcare Expenditure, 2009
Table 29: Pricing and Reimbursement in Generics, Australia, Pharmacy Mark-up Price for PBS Medicines, 2011
Table 30: Pricing and Reimbursement in Generics, Australia, Wholesale Mark-up Price for PBS Medicines, 2011
Table 31: Pricing and Reimbursement in Generics, India, Effect of Jan Aushadhi Shops on Medicines, 2011

1.2 List of Figures

Figure 1: Pricing and Reimbursement in Generics, The US, Other Private and Government Insurance, 2011
Figure 2: Pricing and Reimbursement in Generics, The US, Distribution Channel Logistics and Pricing, 2011
Figure 3: Pricing and Reimbursement in Generics, The US, Comparison Between Fee for Service, HMO and PPO, 2011
Figure 4: Pricing and Reimbursement in Generics, The US, Annual Price Index Change in Prescription Drugs (%), 2008-2010
Figure 5: Pricing and Reimbursement in Generics, The US, Annual Retail Price Index Change in Generic Drugs (%), 2008-2010
Figure 6: Pricing and Reimbursement in Generics, The US, Standard Medicare Part D Benefit, 2011-2020
Figure 7: Pricing and Reimbursement in Generics, The US, Generic Drug Cost-Sharing (%), 2011-2020
Figure 8: Pricing and Reimbursement in Generics, France, LFSS, 2011
Figure 9: Pricing and Reimbursement in Generics, Norway, Stepped Price System, 2011
Figure 10: Pricing and Reimbursement in Generics, China, Healthcare Regulatory Bodies and their Roles, 2011
Figure 11: Pricing and Reimbursement in Generics, India, Factors Determining the Pricing of a Drug, 2011

Note: Product cover images may vary from those shown

RELATED PRODUCTS

Our Clients

Our clients' logos